Skip to main content

Vomiting clinical trials at UCSF

1 research study open to eligible people

Vomiting is when your stomach forcefully empties its contents through your mouth. UCSF is currently conducting a clinical trial for children undergoing intense cancer treatments who experience vomiting. This trial involves testing a medication called Olanzapine to control Chemotherapy-induced nausea and vomiting (CINV).

Showing trials for
  • RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

    open to eligible people ages 30 months to 18 years

    Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy

    San Francisco, California and other locations

Our lead scientists for Vomiting research studies include .

Last updated: